The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model-Reference-Cited by-同舟云学术

The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model

Published:2015-06-25 Issue:26 Volume:125 Page:4032-4041
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Blunt Matthew D.¹,Carter Matthew J.¹,Larrayoz Marta¹,Smith Lindsay D.¹,Aguilar-Hernandez Maria¹²,Cox Kerry L.¹,Tipton Thomas¹,Reynolds Mark¹,Murphy Sarah¹,Lemm Elizabeth¹,Dias Samantha¹,Duncombe Andrew¹³,Strefford Jonathan C.¹,Johnson Peter W. M.¹,Forconi Francesco¹³⁴,Stevenson Freda K.¹,Packham Graham¹,Cragg Mark S.¹,Steele Andrew J.¹^ORCID

Affiliation:

1. Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom;

2. Instituto Nacional de Pediatría, Cuicuilco, Mexico;

3. Hematology Department, Southampton General Hospital, Southampton, United Kingdom; and

4. Cancer Research United Kingdom Centre, National Institute for Health Research, Experimental Cancer Medicine Centre, University of Southampton, Southampton, United Kingdom

Abstract

Key Points PF-04691502 induces potent apoptosis in CLL cells and suppresses prosurvival anti–immunoglobulin M signaling and CXCL12-induced migration. PF-04691502 displays powerful antitumor effects in vivo in the Eμ-TCL1 mouse model.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/26/4032/1387144/4032.pdf

Reference51 articles.

1. The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia.;Kay;Leukemia,2007

2. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.;Hallek;Am J Hematol,2013

3. Molecular and cellular mechanisms of CLL: novel therapeutic approaches.;Pleyer;Nat Rev Clin Oncol,2009

4. Idelalisib: first global approval.;Markham;Drugs,2014

5. Ibrutinib: first global approval.;Cameron;Drugs,2014

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lessons learned from the Eµ-TCL1 mouse model of CLL;Seminars in Hematology;2024-06

2. Inflammation mediated angiogenesis in chronic lymphocytic leukemia;Annals of Hematology;2024-05-07

3. Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides;Scientific Reports;2024-01-23

4. mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia;Leukemia;2023-09-29

5. In-vitro Modulation of mTOR-HIF-1α Axis by TLR7/8 Agonist (Resiquimod) in B-Chronic Lymphocytic Leukemia;Indian Journal of Hematology and Blood Transfusion;2023-04-07